4. Issues of Ethnopharmacology in HIV Management
Summary
Pharmacogenomics is the study of genetic variations that influence individual responses to medications. A polymorphism is a genetic variation at a specific locus on a gene that can affect how a protein works, such as influencing variations in the plasma concentration of a drug. The most common variations in the human genome are single nucleotide polymorphisms (SNPs), and a variant that occurs in > 1% of a population is a SNP. Knowing whether a patient carries a particular SNP can help design therapeutic regimens, increase a drug’s effectiveness, and decrease the probability of adverse events.
A major focus in pharmacogenomics research evaluates the genes that encode either metabolic enzymes that can affect a drug’s activity or defects in proteins that are associated with greater or lesser susceptibility to particular health disorders. Many antiretrovirals are metabolized by enzymes that can be expressed in variable polymorphisms—eg, the CYP2B6 genetic variant that is predictive of higher plasma efavirenz exposure and possibly increased central nervous system adverse events. Another strong association between a genetic variant and antiretroviral response involves the hypersensitivity reaction that can occur with the nucleoside reverse transcriptase inhibitor (NRTI) abacavir. In both cases, the relevant polymorphisms occur in association with a patient’s racial or ethnic background.
The wide variability in individuals’ antiretroviral responses is due to multiple factors, but host genetics play a significant role. Up to 50% of patients discontinue HAART due to adverse drug reactions or virologic failure. With the great diversity of the HIV-positive population and the potential association of HAART failure with racially associated genetic factors, the benefits of minimizing drug toxicities and enhancing virologic efficacy with predictive tests are clear; pharmacogenomics offers the potential to make such benefits a reality. Ongoing research into numerous genetic factors that may be involved in how a person responds to a particular therapy is setting the stage for an era of more personalized antiretroviral treatment.